Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Margaret, Schwartz"'
Autor:
Priya Kumthekar, Madison Lyleroehr, Leilani Lacson, Rimas V. Lukas, Karan Dixit, Roger Stupp, Timothy Kruser, Jeff Raizer, Alexander Hou, Sean Sachdev, Margaret Schwartz, Jessica Bajas PA, Ray Lezon, Karyn Schmidt, Christina Amidei, Karen Kaiser
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Tumor Treating Fields (TTFields) Therapy is an FDA-approved therapy in the first line and recurrent setting for glioblastoma. Despite Phase 3 evidence showing improved survival with TTFields, it is not uniformly utilized. We aimed
Externí odkaz:
https://doaj.org/article/d7895edb0e734564b205c572113db00c
Autor:
Scott A Wu, Dan Tong Jia, Margaret Schwartz, Mary Mulcahy, Kuanghua Guo, Matthew C Tate, Sean Sachdev, Nicolas Kostelecky, David J Escobar, Daniel J Brat, Amy B Heimberger, Rimas V Lukas
Publikováno v:
CNS Oncology, Vol 12, Iss 3 (2023)
Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospe
Externí odkaz:
https://doaj.org/article/71908c412a07460c9e77e4e1c8dc9f98
Autor:
Mario E. Lacouture, Milan J. Anadkat, Matthew T. Ballo, Fabio Iwamoto, Suriya A. Jeyapalan, Renato V. La Rocca, Margaret Schwartz, Jennifer N. Serventi, Martin Glas
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Importance: Tumor Treating Fields (TTFields) are an anti-mitotic treatment approved for treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in glioblastoma comprise alternating electric fields (200 kHz) delivered continuou
Externí odkaz:
https://doaj.org/article/1407100aef504fafbb08d1675907206e
Autor:
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, Nancy U Lin, Eudocia Lee, Sean A Grimm, Margaret Schwartz, Kirsten L Bell Burdett, Rimas V Lukas, Karan Dixit, Isabella Perron, Hui Zhang, William J Gradishar, Elena I Pentsova, Suriya Jeyapalan, Morris D Groves, Michelle Melisko, Jeffrey J Raizer
Publikováno v:
Neuro-Oncology. 25:557-565
Background Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS pen
Autor:
Kirsten Bell Burdett, Dusten Unruh, Michael Drumm, Alicia Steffens, Jonathan Lamano, Jonathan Judkins, Margaret Schwartz, Rodrigo Javier, Christina Amidei, Eric S. Lipp, Katherine B. Peters, Albert Lai, Blaine S. C. Eldred, Amy B. Heimberger, Kathleen McCortney, Denise M. Scholtens, Craig Horbinski
Publikováno v:
Blood.
Venous thromboembolism (VTE) is a life-threating condition that is common in patients with adult-type diffuse gliomas, yet thromboprophylaxis is controversial because of possible intracerebral hemorrhage. Effective VTE prediction models exist for oth
Autor:
Kirsten B Burdett, Dusten Unruh, Michael Drumm, Jonathan Lamano, Margaret Schwartz, James Chandler, Rodrigo Javier, Alicia Steffens, Christina Amidei, Eric S Lipp, Katherine B Peters, Albert Lai, Blaine Eldred, Kathleen McCortney, Amy Heimberger, Denise Scholtens, Craig Horbinski
Publikováno v:
Neuro-Oncology. 24:vii241-vii242
Venous thromboembolism (VTE) is a common paraneoplastic complication in patients with adult-type diffuse gliomas. VTE greatly diminishes quality-of-life, and can even be life-threatening. While effective VTE prediction models exist for other cancers,
Autor:
Priya U, Kumthekar, Michael J, Avram, Andrew B, Lassman, Nancy U, Lin, Eudocia, Lee, Sean A, Grimm, Margaret, Schwartz, Kirsten L, Bell Burdett, Rimas V, Lukas, Karan, Dixit, Isabella, Perron, Hui, Zhang, William J, Gradishar, Elena I, Pentsova, Suriya, Jeyapalan, Morris D, Groves, Michelle, Melisko, Jeffrey J, Raizer
Publikováno v:
Neuro-oncology.
Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS penetration. T
Autor:
Margaret Schwartz
Publikováno v:
New Media & Society. 22:1324-1326
Autor:
Howard Colman, Si Chen, C. David James, Laura Zuckerman, Olga Antipova, Margaret Schwartz, Daniel J. Brat, Junjing Deng, Dusten Unruh, Mitchell Glass, Caroline H. Ko, Rimas V. Lukas, Orin Bloch, Gayle E. Woloschak, Priya Kumthekar, Barry Lai, Ramana V. Davuluri, Fotini M. Kouri, Craig Horbinski, Borko Jovanovic, Tatjana Paunesku, Vinod Vijayakumar, Ray Lezon, Lisa A. Hurley, Miguel Muzzio, Nitya V. Sharma, Adam M. Sonabend, Francis J. Giles, Jeremy Heidel, Ann K. Adams, Matthew C. Tate, Serena Tommasini-Ghelfi, Luxi Li, Kathleen McCortney, Alexander H. Stegh, Manoj Kandpal, Karan Dixit
Publikováno v:
Science translational medicine, vol 13, iss 584
Sci Transl Med
Sci Transl Med
The lack of precision therapies combined with limited therapeutic access to intracranial tumor sites due to the presence of the blood-brain/blood-tumor barriers have contributed to glioblastoma (GBM) being one of the most difficult cancers to effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b32e3981c0cbcca50f68f14a1475576
https://escholarship.org/uc/item/5601p8jn
https://escholarship.org/uc/item/5601p8jn
Autor:
Michael Drumm, Christina Amidei, Craig Horbinski, Kathleen McCortney, Denise M. Scholtens, Kirsten Bell Burdett, Margaret Schwartz, Anh Nhat Tran, Jonathan B. Lamano, Rodrigo Javier, Dusten Unruh
Publikováno v:
Neuro-Oncology. 23:vi16-vi16
BACKGROUND Venous thromboembolism (VTE) is a debilitating and life-threating condition that is common in patients with cancer, especially glioma. There are no widely-accepted guidelines for antithrombotic prophylaxis in glioma patients, in part becau